Current Cancer Drug Targets

Editor-in-Chief

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)

Personal Subscription
Become EABM
Become Reviewer
Call for Editor

Abstract Ahead of Print

MiR-129-5p promotes radio-sensitivity of NSCLC cells by targeting SOX4 and RUNX1

Tongqing Xue, Gang Yin, Weixuan Yang, Xiaoyu Chen, Cheng liu, Weixi Yang* and Jun Zhu*

NONO-TFE3 fusion promotes aerobic glycolysis and angiogenesis by targeting HIF1A in NONO-TFE3 translocation renal cell carcinoma

Yi Chen, Lei Yang, Ning Liu, Qiancheng Shi, Xiaoqin Yin, Xiaodong Han, Weidong Gan* and Dongmei Li*

The Clinical Application of Circulating Tumor Cells and DNAs as Prognostic and Predictive Biomarkers in Gastrointestinal Cancer

Sara Memarpour*, Ghazaleh Khalili-Tanha*, Awa Alizadeh Ghannad, Masoud Sharifian Razavi, Mona Joudi, Marjan Joodi, Gordon A. Ferns, Seyed Mahdi Hassanian, Majid Khazaei and Amir Avan*

Oncolytic adenoviral H101 synergizes with radiation in cervical cancer cells

Yixin Duan, Haixia Bai, Xiang Li , Depu Wang , Yin Wang, Meng Cao, Nana Zhang, Hongwei Chen * and Yili Wang*

The curcumin analog EF24 is highly active against chemotherapy-resistant melanoma cells

Yonghan He*, Wen Li, Junling Zhang, Yang Yang, Ya-Wei Qian and Daohong Zhou

Association of Polymorphism in Survivin gene and the risk of Liver Cancer resulting from Hepatitis C Virus among Egyptian patients

Amal A. Mohamed, Aymen S. Yassin, Basma S. Gomaa, Hossam Darwish, Rasha S. Mohamed, Sahar Makled, Ahmed Ramdan, Sherief Abd-Elsalam* and Marwa M. Raafat

Nanotechnology-Enabled Chemodynamic & Immunotherapy

Taixia Wang, Xiaohong Xu and Kun Zhang*